OncoCyte Total Non-Operating Income/Expense 2014-2024 | OCX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OncoCyte total non-operating income/expense from 2014 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

OncoCyte Total Non-Operating Income/Expense 2014-2024 | OCX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OncoCyte total non-operating income/expense from 2014 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$91.4B
Cencora (COR)	$47.5B
DiDi Global (DIDIY)	$23.3B
Natera (NTRA)	$21.4B
ICON (ICLR)	$16.1B
Viatris (VTRS)	$15.6B
Avantor (AVTR)	$13.4B
Revvity (RVTY)	$13.4B
CochLear (CHEOY)	$12.8B
BioMerieux (BMXMF)	$12.7B
Solventum (SOLV)	$11.6B
Medpace Holdings (MEDP)	$9.8B
Doximity (DOCS)	$9.6B
Charles River Laboratories (CRL)	$9.5B
HealthEquity (HQY)	$9B
Sonic Healthcare (SKHHY)	$8.8B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Sotera Health (SHC)	$3.9B
Organon (OGN)	$3.8B
BrightSpring Health Services (BTSG)	$3.2B
Surgery Partners (SGRY)	$2.9B
PACS (PACS)	$2.6B
Concentras Parent (CON)	$2.6B
Ardent Health Partners (ARDT)	$2.4B
Premier (PINC)	$2.1B
Alignment Healthcare (ALHC)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GeneDx Holdings (WGS)	$2B
GoodRx Holdings (GDRX)	$1.6B